Man Group plc Has $137.26 Million Position in Edwards Lifesciences Corporation $EW

Man Group plc lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 18.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,610,036 shares of the medical research company’s stock after selling 357,397 shares during the quarter. Man Group plc’s holdings in Edwards Lifesciences were worth $137,256,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. JPL Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the third quarter valued at $25,000. Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $27,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $28,000. Hilton Head Capital Partners LLC acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at $28,000. Finally, Dorato Capital Management bought a new position in Edwards Lifesciences in the fourth quarter valued at about $29,000. 79.46% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Daniel J. Lippis sold 620 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $81.14, for a total value of $50,306.80. Following the sale, the vice president owned 40,411 shares in the company, valued at approximately $3,278,948.54. The trade was a 1.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 81,038 shares of company stock valued at $6,683,255. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

Shares of EW opened at $86.53 on Thursday. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $89.60. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The company has a market capitalization of $49.83 billion, a price-to-earnings ratio of 46.03, a price-to-earnings-growth ratio of 2.22 and a beta of 0.87. The business has a 50-day moving average of $83.14 and a 200-day moving average of $83.11.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.05. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. During the same quarter in the previous year, the company earned $0.64 EPS. Edwards Lifesciences’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on EW shares. Truist Financial set a $90.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, April 24th. Robert W. Baird lifted their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Evercore reiterated an “outperform” rating and set a $93.00 target price on shares of Edwards Lifesciences in a research note on Friday, April 24th. Finally, BTIG Research boosted their price target on Edwards Lifesciences from $98.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.96.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.